----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 15, 2008 10:09:30 AM
Subject: Prognostic role of osteopontin expression in malignant pleural mesothelioma.
[1]Am J Clin Pathol. 2008 Jul; 130(1): 58-64
Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV, Papotti M
Malignant pleural mesothelioma (MPM) represents highly aggressive neoplasms with a mean survival of approximately 10 months. Osteopontin, a glycoprotein involved in cell-matrix interactions correlated with invasion and metastatic spread in several tumors, has recently been proposed as a serum marker of MPM in asbestos-exposed subjects. The aim of this study was to define the prognostic role of osteopontin in MPM. For the study, 32 long-term survivors (>24 months) and a random sample of 69 short-term survivors (
___
Source: http://www.hubmed.org/display.cgi?uids=18550471
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 15, 2008 10:09:30 AM
Subject: Prognostic role of osteopontin expression in malignant pleural mesothelioma.
[1]Am J Clin Pathol. 2008 Jul; 130(1): 58-64
Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, Molinaro L, Scagliotti GV, Papotti M
Malignant pleural mesothelioma (MPM) represents highly aggressive neoplasms with a mean survival of approximately 10 months. Osteopontin, a glycoprotein involved in cell-matrix interactions correlated with invasion and metastatic spread in several tumors, has recently been proposed as a serum marker of MPM in asbestos-exposed subjects. The aim of this study was to define the prognostic role of osteopontin in MPM. For the study, 32 long-term survivors (>24 months) and a random sample of 69 short-term survivors (
___
Source: http://www.hubmed.org/display.cgi?uids=18550471
--
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc